Intellia Therapeutics, Inc. (NASDAQ:NTLA) headquartered in Cambridge, will host a conference call for the investment community to discuss the 3Q20 earnings result on 5th November 2020 at 8:00 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.intelliatx.com
Earnings Expectation
Intellia Therapeutics, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, NTLA to report 3Q20 loss of $ 0.59 per share. For the full year, analysts anticipate top line of $ 58.18 million, while looking forward to loss of $ 2.49 per share bottom line.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia.
